Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

NCT04877132 | Unknown

• 1 other identifier: RHASHC09706
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this program is to provide access to enzyme replacement therapy (ERT) with olipudase alfa for certain patients with ASMD, a severe, life threatening disease, that could not participate in the olipudase clinical trials. The program will provide access to olipudase alfa prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.

Conditions

Sphingomyelin Lipidosis

Interventions

olipudase alfa (GZ402665) DRUG

Patients will receive intravenous (IV) infusion of olipudase alfa

Eligibility Criteria

• Age: 3 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients (adult and pediatric)
• Unsolicited request for the patient from a site with at least 3 years of experience in administration and safety management of ERT.
• Written informed consent signed by the patient or the patient's parent(s)/guardian(s), where applicable.
• Documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes, or cultured fibroblasts.
• Adult patients
• Age ≥ 18 years.
• Clinically documented advanced disease evidenced by defined thresholds for lung, spleen, liver, and hematologic parameters.
• Pediatric patients
• \- Age \>3 years and \<18 years or clinical diagnosis consistent with ASMD Type A/B or Type B.

You may not qualify if:

• All patients (adult and pediatric)
• Active serious intercurrent illness which will preclude enrollment, significant liver disease with etiology other than ASMD, Malignancy with poor prognosis, serious medical or psychiatric condition that may preclude participation, or circumstances that may interfere with compliance in this compassionate use program, requirement for recurrent dose adjustment of anticoagulation treatment over the last 6 months.
• Pregnancy or breastfeeding.
• For female patients of childbearing potential, a positive serum pregnancy (β human chorionic gonadotropin \[HCG\]) test result.
• For female patients of childbearing potential and sexually active male patients, unwillingness to abstain from heterosexual intercourse in accordance with their preferred and usual lifestyle, or to use 2 acceptable, effective contraceptive methods, while participating in this program and for 15 days after the last infusion of olipudase alfa.
• For pediatric patients, clinical diagnosis, or suspicion of infantile onset ASMD. Genotype compatible with ASMD type A.

Sponsors & Collaborators

• Sanofi: lead

MeSH Terms

Conditions

Niemann-Pick Disease, Type A

Interventions

olipudase alfa

Condition Hierarchy (Ancestors)

Niemann-Pick Diseases; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Lipidoses; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Lipid Metabolism Disorders

Study Officials

• Clinical Sciences & Operations

  Sanofi

  STUDY DIRECTOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 3, 2021
• First Posted: May 7, 2021
• Last Updated: September 19, 2022

Record last verified: 2022-09